Cibenzoline (CAS 53267-01-9)
QUICK LINKS
Cibenzoline is a compound extensively used in cardiac electrophysiology research due to its sodium channel-blocking effects, which provide valuable insights into the mechanisms underlying cardiac arrhythmias. Its role in modulating the activity of cardiac sodium channels makes it a focus for studies on the structure-activity relationships for the development of selective ion channel modulators. Beyond the heart, cibenzoline′s impact on neuronal and skeletal muscle sodium channels offers broader insights into sodium-dependent action potentials and excitable cell physiology. Additionally, as a reference compound, cibenzoline aids in the assessment of novel sodium channel inhibitors, with research delving into its binding specificity and the biophysical alterations it triggers, thereby enriching the understanding of ion channel modulation.
Cibenzoline (CAS 53267-01-9) References
- The relationship between risk of hypoglycemia and use of cibenzoline and disopyramide. | Takada, M., et al. 2000. Eur J Clin Pharmacol. 56: 335-42. PMID: 10954349
- Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase. | Tabuchi, Y., et al. 2001. Br J Pharmacol. 134: 1655-62. PMID: 11739241
- Decrease in the spatial dispersion at the termination of atrial fibrillation by intravenous cibenzoline. | Kakugawa, H., et al. 2003. Circ J. 67: 810-5. PMID: 14578610
- Block of HERG current expressed in HEK293 cells by the Na+-channel blocker cibenzoline. | Hiramatsu, M., et al. 2004. Heart Vessels. 19: 137-43. PMID: 15168062
- Pharmacodynamics of cibenzoline-induced hypoglycemia in rats. | Takahashi, Y., et al. 2011. Drug Metab Pharmacokinet. 26: 242-7. PMID: 21273730
- Inhibitory effect of cibenzoline on Na+/Ca2+ exchange current in guinea-pig cardiac ventricular myocytes. | Yamakawa, T., et al. 2012. J Pharmacol Sci. 120: 59-62. PMID: 22971843
- Efficacy of cibenzoline for hypertrophic obstructive cardiomyopathy in paediatric patients with RAS/MAPK pathway syndromes. | Watanabe, K., et al. 2022. Cardiol Young. 1-3. PMID: 36221307
- Characterization of the class I antiarrhythmic activity of cibenzoline succinate in guinea pig papillary muscle. | Arena, JP., et al. 1987. J Pharmacol Exp Ther. 240: 441-50. PMID: 3806408
- Biotransformation of cibenzoline to 2-(2,2-diphenylcyclopropyl)-1H-imidazole. | Leinweber, FJ., et al. 1983. Xenobiotica. 13: 287-94. PMID: 6636825
- Molecular mechanism of cibenzoline-induced anticholinergic action in single atrial myocytes: comparison with effect of disopyramide. | Wu, SN., et al. 1994. J Cardiovasc Pharmacol. 23: 618-23. PMID: 7516012
- Block of pancreatic ATP-sensitive K+ channels and insulinotrophic action by the antiarrhythmic agent, cibenzoline. | Ishida-Takahashi, A., et al. 1996. Br J Pharmacol. 117: 1749-55. PMID: 8732286
- Na+ channel blocking effects of cibenzoline on guinea-pig ventricular cells. | Niwa, R., et al. 1998. Eur J Pharmacol. 352: 317-27. PMID: 9716369
- The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. | Mukai, E., et al. 1998. Biochem Biophys Res Commun. 251: 477-81. PMID: 9792799
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cibenzoline, 10 mg | sc-268718 | 10 mg | $209.00 |